These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37715448)

  • 21. Choosing Dipeptidyl Peptidase-4 Inhibitors, Sodium-glucose Cotransporter-2 Inhibitors, or Both, as Add-ons to Metformin: Patient Baseline Characteristics Are Crucial.
    Goldenberg RM
    Clin Ther; 2017 Dec; 39(12):2438-2447. PubMed ID: 29174215
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Primary care management of type 2 diabetes: a comparison of the efficacy and safety of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
    Campos C; Unger J
    Postgrad Med; 2021 Nov; 133(8):843-853. PubMed ID: 34416133
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of Combination Therapy of Canagliflozin Added to Teneligliptin Monotherapy in Japanese Subjects with Type 2 Diabetes Mellitus: A Retrospective Study.
    Fushimi Y; Obata A; Sanada J; Iwamoto Y; Mashiko A; Horiya M; Mizoguchi-Tomita A; Nishioka M; Kan Y; Kinoshita T; Okauchi S; Hirukawa H; Kohara K; Tatsumi F; Shimoda M; Nakanishi S; Mune T; Kaku K; Kaneto H
    J Diabetes Res; 2020; 2020():4861681. PubMed ID: 32337293
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Imeglimin: features of the mechanism of action and potential benefits].
    Kuznetsov KO; Saetova AA; Mahmutova EI; Bobrik AG; Bobrik DV; Nagaev IR; Khamitova AD; Arapieva AM
    Probl Endokrinol (Mosk); 2022 Mar; 68(3):57-66. PubMed ID: 35841169
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stimulatory effect of imeglimin on incretin secretion.
    Yingyue Q; Sugawara K; Takahashi H; Yokoi N; Ohbayashi K; Iwasaki Y; Seino S; Ogawa W
    J Diabetes Investig; 2023 Jun; 14(6):746-755. PubMed ID: 36977210
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of Sodium-Glucose Cotransporter 2 Inhibitor vs Dipeptidyl Peptidase-4 Inhibitor Use With Risk of Incident Obstructive Airway Disease and Exacerbation Events Among Patients With Type 2 Diabetes in Hong Kong.
    Au PCM; Tan KCB; Lam DCL; Cheung BMY; Wong ICK; Kwok WC; Sing CW; Cheung CL
    JAMA Netw Open; 2023 Jan; 6(1):e2251177. PubMed ID: 36648944
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers.
    Kishimoto M; Noda M
    Cardiovasc Diabetol; 2011 Dec; 10():115. PubMed ID: 22189184
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of Dapagliflozin on Glycemic Variability in Patients with Type 2 Diabetes under Insulin Glargine Combined with Other Oral Hypoglycemic Drugs.
    Luo M; Kong X; Wang H; Zhai X; Cai T; Ding B; Hu Y; Jing T; Su X; Li H; Ma J
    J Diabetes Res; 2020; 2020():6666403. PubMed ID: 33299890
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes.
    Mu J; Petrov A; Eiermann GJ; Woods J; Zhou YP; Li Z; Zycband E; Feng Y; Zhu L; Roy RS; Howard AD; Li C; Thornberry NA; Zhang BB
    Eur J Pharmacol; 2009 Nov; 623(1-3):148-54. PubMed ID: 19765579
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of adverse respiratory events with sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors among patients with type 2 diabetes in South Korea: a nationwide cohort study.
    Jeong HE; Park S; Noh Y; Bea S; Filion KB; Yu OHY; Jang SH; Cho YM; Yon DK; Shin JY
    BMC Med; 2023 Feb; 21(1):47. PubMed ID: 36765407
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Newer second-line glucose-lowering drugs versus thiazolidinediones on cirrhosis risk among older US adult patients with type 2 diabetes.
    Yang JY; Moon AM; Kim H; Pate V; Barritt AS; Crowley MJ; Buse JB; Stürmer T; Alexopoulos AS
    J Diabetes Complications; 2020 Nov; 34(11):107706. PubMed ID: 32843283
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improving the Effects of Imeglimin on Endothelial Function: A Prospective, Single-Center, Observational Study.
    Uchida T; Ueno H; Konagata A; Taniguchi N; Kogo F; Nagatomo Y; Shimizu K; Yamaguchi H; Shimoda K
    Diabetes Ther; 2023 Mar; 14(3):569-579. PubMed ID: 36732433
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-world effectiveness of imeglimin in patients with type 2 diabetes: A retrospective longitudinal study in Japan.
    Katsuyama H; Hakoshima M; Heshiki T; Iida S; Adachi H; Yanai H
    Diabetes Res Clin Pract; 2024 Jul; 213():111752. PubMed ID: 38908549
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Risk of Kidney Outcomes: Emulation of a Target Trial Using Health Care Databases.
    Xie Y; Bowe B; Gibson AK; McGill JB; Maddukuri G; Yan Y; Al-Aly Z
    Diabetes Care; 2020 Nov; 43(11):2859-2869. PubMed ID: 32938746
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness and safety of new oral and injectable agents for in-hospital management of type 2 diabetes in general wards: Systematic review and meta-analysis.
    Soto-Chávez MJ; Muñoz-Velandia OM; Alzate-Granados JP; Lombo CE; Henao-Carrillo DC; Gómez-Medina AM
    Diabetes Res Clin Pract; 2022 Sep; 191():110019. PubMed ID: 35931222
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SGLT2i increased the plasma fasting glucagon level in patients with diabetes: A meta-analysis.
    Zhu X; Lin C; Li L; Hu S; Cai X; Ji L
    Eur J Pharmacol; 2021 Jul; 903():174145. PubMed ID: 33957085
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase 2 trial with imeglimin in patients with Type 2 diabetes indicates effects on insulin secretion and sensitivity.
    Theurey P; Thang C; Pirags V; Mari A; Pacini G; Bolze S; Hallakou-Bozec S; Fouqueray P
    Endocrinol Diabetes Metab; 2022 Nov; 5(6):e371. PubMed ID: 36239048
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus.
    Triplitt C; Solis-Herrera C; Cersosimo E; Abdul-Ghani M; Defronzo RA
    Expert Opin Pharmacother; 2015; 16(18):2819-33. PubMed ID: 26583910
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes.
    Zhou J; Liu X; Chou OH; Li L; Lee S; Wong WT; Zhang Q; Chang C; Liu T; Tse G; Jing F; Cheung BMY
    Rheumatology (Oxford); 2023 Apr; 62(4):1501-1510. PubMed ID: 36066415
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.